Skip to main content

Advertisement

Table 1 Demographic & clinical characteristics by treatment group

From: Symptom burden & quality of life among patients receiving second-line treatment of metastatic colorectal cancer

Variables Chemotherapy only N = 38 Cetuximab N = 38 BevacizumabN = 106 Total N = 182
Gender, n (%)
Female 23 (60.5%) 14 (36.8%) 56 (52.8%) 93 (51.1%)
Age (years)
Mean (SD) 60.8 (14.7) 64.6 (11.2) 61.5 (12.3) 62.0 (12.6)
US Region, n (%)
Northeast 4 (10.5%) 3 (7.9%) 3 (2.8%) 10 (5.5%)
Midwest 0 (0.0%) 2 (5.3%) 4 (3.8%) 6 (3.3%)
South 27 (71.1%) 28 (73.7%) 83 (78.3%) 138 (75.8%)
West 7 (18.4%) 5 (13.2%) 16 (15.1%) 28 (15.4%)
Race, n (%)
White 26 (68.4%) 26 (68.4%) 71 (67.0%) 123 (67.6%)
Minority 12 (31.6%) 12 (31.6%) 35 (33.0%) 59 (32.4%)
Sub-Total 38 (100%) 38 (100%) 106 (100%) 182 (100%)
BMI
Mean (SD) 26.3 (6.2) 28.9 (5.2) 26.9 (5.4) 27.2 (5.6)
Disease Stage, n (%)
Stage IV 38 (100%) 38 (100%) 106 (100%) 182 (100%)
ECOG, n (%)
0 8 (21.1%) 10 (26.3%) 19 (17.9%) 37 (20.3%)
1 8 (21.1%) 6 (15.8%) 19 (17.9%) 33 (18.1%)
2+ 2 (5.3%) 3 (7.9%) 3 (2.8%) 8 (4.4%)
Text indication of impairment 4 (10.5%) 2 (5.3%) 14 (13.2%) 20 (11.0%)
No text indication of impairment 16 (42.1%) 17 (44.7%) 51 (48.1%) 84 (46.2%)
Sites of Distant Metastasis, n (%) *
Liver 24 (63.2%) 24 (63.2%) 71 (67.0%) 119 (65.4%)
Lung 14 (36.8%) 21 (55.3%) 50 (47.2%) 85 (46.7%)
Peritoneum 9 (23.7%) 6 (15.8%) 28 (26.4%) 43 (23.6%)
Small intestine 0 (0%) 0 (0%) 4 (3.8%) 4 (2.2%)
Other 16 (42.1%) 15 (39.5%) 47 (44.3%) 78 (42.9%)
Not documented 0 (0%) 0 (0%) 1 (0.9%) 1 (0.5%)
  1. * Patients may be represented on more than one row.